Roche’s Parkinson’s disease drug candidate misses key target in mid-stage study

An experimental drug for Parkinson’s disease failed to meet its primary endpoint in a mid-stage trial, Roche said, the second setback this week for candidate treatments for the condition. neurodegeneration.